The MS Symptom and Impact Diary (MSSID): psychometric 

evaluation of a new instrument to measure the day to day impact of multiple sclerosis by Greenhalgh, J et al.
PAPER
The MS Symptom and Impact Diary (MSSID): psychometric
evaluation of a new instrument to measure the day to day
impact of multiple sclerosis
J Greenhalgh, H Ford, AF Long, K Hurst
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Received 16 June 2003
In revised form
28 August 2003
Accepted 29 August 2003
. . . . . . . . . . . . . . . . . . . . . . .
J Neurol Neurosurg Psychiatry 2004;75:577–582. doi: 10.1136/jnnp.2003.020529
Objectives: This study aimed to develop further a diary originally devised to measure the impact of multiple
sclerosis (MS) as part of a cost utility study of beta interferon, and to evaluate its reliability, validity, and
responsiveness in an outpatient sample of people with MS.
Methods: The original diary was further developed using qualitative and quantitative methods to ensure
that it addressed the views of people with MS. The psychometric properties of the MS Symptom and Impact
Diary (MSSID) were evaluated in a sample of 77 people who completed the MSSID daily for 12 weeks.
Internal and test–retest reliability, discriminant and convergent validity, and responsiveness were assessed
using traditional psychometric methods.
Results: The MSSID formed three, internally consistent scales that measured mobility, fatigue, and the
overall impact of MS. The test–retest reliability of the mobility scale was adequate for individual
comparisons (ICC.0.90) and the fatigue and overall impact scales were adequate for group comparisons
(ICC.0.70). The MSSID was able to distinguish between clinical groups depending on clinical course,
indoor ambulation status, and relapse status. It demonstrated associations with other single point
instruments in the expected direction. Compared with single point instruments, its responsiveness was
similar or better, especially in detecting short term improvements in functioning.
Conclusions: The MSSID may provide a useful complement to currently available instruments to measure
the outcomes of MS within clinical trials. Further research is needed to explore its feasibility in the context
of a randomised controlled trial and its utility for clinicians.
T
he importance of measuring outcomes from the perspec-
tive of people with multiple sclerosis (MS) has recently
become more widely recognised.1 2 People with MS
have different concerns to clinicians regarding the most
important areas in which MS affects their lives; clinicians
place more importance on the physical aspects of the
condition, while patients are more concerned with mental
health and vitality.3 The relationship between clinical
assessments of disability and those of the patient have also
typically been low.4 5 Moreover, disease modifying treatments
for MS, such as beta interferon, may produce benefits that
are significant to the patient but are not measured by clinical
assessments.6
The content of outcome measures needs to reflect the
issues that people with MS consider to be important.7 It is
only recently that disease specific instruments to measure the
outcomes of MS have been developed using a patient centred
approach. These include instruments such as the Leeds MS
quality of life scale (LMSQoL)8 and the MS Symptom and
Impact Scale-29 (MSIS-29)9 10 both of which have been
shown to be reliable, valid, and responsive to change.
Such instruments represent a significant contribution to
the measurement of outcomes from the perspective of people
with MS. However, they are not equipped to measure a
central feature of MS as a disease that has a significant effect
on the lives of people with MS, namely the day to day
variability of symptoms and their impact.11 12 The variable
and unpredictable nature of MS makes it difficult for people
with MS to plan their lives or be spontaneous, and results in
increased levels of psychological distress,13 14 but is rarely
measured in clinical trials or in clinical practice. The
ambiguous and transient nature of many MS symptoms
can also make it difficult for people with MS and for
clinicians to identify when a relapse has occurred and when
recovery begins.15 16
There is a need for new ways of assessing the outcomes of
MS that take account of its variable nature. Increased
importance should be placed on the use of symptom diaries
in trials to accurately document the onset and resolution of
relapses and symptoms.15 Diaries have been frequently used
as outcome measures in randomised controlled trials of
chronic diseases.17–19 They can provide a more comprehensive
view of people’s health problems and enable the investigation
of short and long term changes in health patterns over
time.18 19 20 They have also been used to measure the quality
of life of people with MS more comprehensively within a
study of the cost utility of beta interferon, but as yet, the
psychometric properties of this diary have not been tested.21
This paper reports on a study that modified and extended this
diary,21 with reference to the views of people with MS, and
assessed its validity, reliability, and responsiveness in an
outpatient sample of people with MS using traditional
psychometric methods.23 24
METHODS
Development of the MSSID
The MSSID was developed further in three phases. Firstly,
two focus groups (n = 8 and n = 5) and ten in depth
interviews with a purposively selected sample of people with
MS, recruited from a community based population, explored
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the impact of MS and the relevance of diaries. Their views
were used to modify the original diary.21 Secondly, the
modified diary was pre-tested with nine people with MS
using "think aloud" interviews,25 in which respondents gave a
verbal report of their thought processes as they completed the
diary to identify difficulties with the phrasing or response
options of the items. Thirdly, the refined diary was piloted
with 14 people with MS recruited from outpatient clinics,
who completed the diary for 14 consecutive days. The final
version of the MSSID (see appendix 1), in the form of an A5
booklet, comprised eight items. Two items (Q1 and Q2) asked
about the experience and impact of 14 MS related problems
on daily activities, four items (Q4–Q6) asked about the
overall impact of MS, one item (Q7) compared health today
with health yesterday, and the final item (Q8) left space for
respondents to note down anything else that they considered
to be important. This version of the MSSID formed the focus
for psychometric assessment.
Participants
The psychometric properties of the MSSID were assessed in a
sample of 77 people with MS recruited from outpatient clinics
in two centres, between September and October 2000. People
with MS attending the clinic were eligible if they were diag-
nosed with MS, aware of their diagnosis, and aged between
18 and 65 years. Those unable to complete a questionnaire
owing to cognitive impairment were excluded. Those who had
been diagnosed with MS for less than 1 year and those who
were judged by the clinician to be experiencing difficulties
dealing with their diagnosis were also excluded, to avoid the
possibility of causing undue distress. The study was approved
by the relevant local research ethics committees, and all
participants gave written informed consent before taking part.
Instruments
At recruitment, the mobility status of all participants was
rated according to whether they moved around the clinic
unaided or used a walking aid. Participants were asked to
complete three consecutive, 4 week diaries. At baseline and
at the end of the 12 week study, participants completed a
postal questionnaire. This included the LMSQoL8 as a
measure of quality of life; the MSQoL-5426 as a measure of
health status (the sexual functioning items were excluded as
they have been found to be poorly completed27 and did not
reflect the content of the diary); the postal Barthel Index28 as
a measure of disability/functioning; and the London
Handicap Scale (LHS)29 and the Reintegration to Normal
Living Index (RNLI)30 as measures of handicap or participa-
tion. At the end of each 4 week diary period, participants
completed a questionnaire asking about changes to symp-
toms and MS overall, medication, and relapses using
questions from the cost utility study.21
Data quality
Data quality was assessed by examining response rates,
missing items, and score distributions.
Reliabili ty
Both internal and test2retest reliability were assessed. The
internal structure of the MSSID was examined using
principal components analysis with varimax rotation on
three randomly selected days, one from each 4 week diary
period. Two sets of analyses were performed, one for the
symptom items (Q2) and one for the impact items (Q3–Q6).
Factors were entered into the rotation if they had an
eigenvalue of 1 or more, and loadings of 0.4 and above were
used to determine which items belonged to which factor.31
The item content of the resulting factors were independently
reviewed by a consultant neurologist (HF) to ensure they
made clinical sense. Factor scores for each day were
calculated by summing the items in each factor and then
dividing by the total number of items completed within the
factor that day. Higher scores indicated better functioning.
The internal reliability of the resulting factors was assessed
using Cronbach’s alpha32 and item total correlations on three
randomly selected days, one from each month. Reliability
was deemed adequate if Cronbach’s alphas were .0.824 and
item total correlations .0.2.23
The test2retest reliability of the resulting factors was
assessed in two ways using the intraclass correlation
coefficient (ICC).33 Firstly, the ICC was calculated between
median week 1 and week 4 factor scores in stable
respondents—that is, those whose symptoms did not change
and who did not have a relapse during the first 4 weeks
(n = 26). Secondly, the ICC was calculated between factor
scores on the first 2 days of each 4 week diary period when
the respondent indicated that their health had not changed
(n = 61). ICCs between 0.70 and 0.89 were deemed adequate
for group comparisons, while ICCs of 0.9 and above were
deemed adequate for individual comparisons.24
Validity
Both discriminant and convergent construct validity were
assessed using appropriate summary indicators of the long-
itudinal diary data.34 To provide a summary indicator of the
impact of symptoms on daily activities (factors 1 and 2) and
the impact of MS overall (factor 3), median factor scores were
used. The median was chosen rather than the mean as it was
expected that the median would be less influenced by
missing data, and it was not expected that an individual’s
scores over time would be normally distributed.
Previous research has demonstrated that people with
progressive MS experience greater levels of impairment and
disability than other disease course groups,35 and that people
who have had a relapse experience worse health status than
those who have not.21 Therefore, it was hypothesised that
there would be statistically significant differences in median
factor scores between those with relapsing remitting or
benign MS v those with progressive MS, between those who
walked unaided v those who used a walking aid and between
those who experienced a relapse during the study v those
who did not. In each case it was expected that for patients
with progressive MS, those who used a walking aid and those
who had a relapse would have worse (lower) median factor
scores.
The convergent validity of the MSSID was examined by
exploring correlations between the median factor scores
during the last 4 week diary period and single point
instruments collected at the end of the study. Correlations
,0.4 were considered small, between 0.41 and 0.7 moderate,
and 0.71 and above high.9
Responsiveness
Effect sizes of the change in median MSSID scores, LMSQoL,
and MSQol-54 scores between week 1 and week 4 were
calculated separately for those who indicated that their MS
had got better (n = 14) and those who indicated that their
MS had got worse (n = 20) in the first 4 weeks of the study.36
Effect sizes of 0.2 were considered to be small, 0.5 moderate,
and 0.8 or more large.37 It was expected that effect sizes for
the MSSID scores and MSQol-54 would be positive for those
who got better and negative for those who got worse. The
reverse pattern was expected for the LMSQoL because higher
scores indicate worse functioning.
Statistical analyses
The differences in continuous variables (for example, MSSID
scores) were assessed using Mann-Whitney U tests.
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Differences in categorical variables were assessed using the x2
test. Relationships between MSSID factor scores and single
point instruments were assessed using Spearman’s rank
correlations. All analyses were carried out in SPSS for
Windows (version 9).
RESULTS
Changes made to the original diary
A number of changes were made to the original diary
following the developmental stages. Seven symptom items
were added to reflect issues that were raised in focus groups
and interviews (for example "difficulties thinking clearly or
forgetting things" and "feeling frustrated"). Some items were
reworded to make them more interpretable to respondents
(for example "altered sensations" was changed to "altered or
loss of sensation"). The number of response options of some
items was increased to better reflect the variation in symptom
impact and health perceptions (for example, the response
options for Q6 were reworded and increased from three to
six). Finally, an open ended question (Q8) was added to
allow respondents to record any additional issues or events
that happened.
Sample characteristics
Sixty three people (82%) returned all three diaries; these
were classed as respondents and used in subsequent
analyses. Eighty one percent were women, the average age
was 46 years, and they had been diagnosed with MS for an
average of 11 years (table 1). Seventy three percent were
currently not in paid work and 33% had experienced a relapse
during the study. There were no statistically significant
differences in age, gender, length of time since diagnosis, or
clinical course between respondents recruited from either
centre, thus the two samples were analysed together.
Data quality
Across the entire 12 weeks, 7% of MSSID items were missing,
ranging from 5.8% to 7.6% across items. Three quarters of
respondents completed at least 93% of the items and all
respondents completed at least 50% of the items. Three
symptom impact items (Q2) "weakness or heaviness in your
legs", "problems with your bladder and bowel", and "feeling
frustrated", had floor effects, with 20% or more person days
rated as "a lot".
Internal reliability
The factor analysis of symptom impact items (Q2) revealed
three factors that explained between 62% and 68% of the
total variance. However, one factor contained only two items
("blurred, double, or shaky vision" and "coughing or choking
when eating and drinking") and performed poorly in the
internal reliability analyses, thus it was not retained. The
remaining two symptom impact factors measured "mobility"
and "fatigue". The factor analysis of the overall impact items
(Q3–Q6) formed one factor that explained between 66% and
79% of the total variance and measured the overall impact of
MS. For the three retained factors, Cronbach’s alpha
exceeded or approached 0.8 and item total correlations
exceeded 0.2 (table 2).
Test–retest reliability
For both weekly factor median scores and daily factor score
comparisons, the ICC for fatigue and overall impact exceeded
0.7 and for mobility, exceeded 0.9 (table 2).
Discriminant validity
There were statistically significant differences in the overall
impact scores between all the clinical groups in the expected
direction (table 3). For mobility, there were statistically
significant differences between all clinical groups in the
expected direction with the exception of the relapse/no
relapse comparison. For fatigue there were statistically
significant differences between all clinical groups in the
expected direction with the exception of the relapsing
remitting/benign v progressive MS comparison. There were
no statistically significant differences in the median factor
scores between those recruited from either centre (data
available on request).
Convergent validity
Table 4 shows the Spearman’s rank correlation coefficients
between median factor scores during the last four weeks and
the single point instruments collected at the end of the study.
Mobility showed moderate correlations with the MSQol-54
physical and social functioning scales and with the RNLI.
Fatigue showed moderate correlations with the MSQol-54
energy and emotional wellbeing scales and the RNLI. Overall
impact of MS showed moderate correlations with the RNLI,
the LMSQoL, MSQol-54 social function, and overall quality of
life. The factor scores were all highly related to each other
and were more highly related to each other than to the single
point instruments. Fatigue and mobility were more highly
related to each other than to overall impact of MS.
Responsiveness
Effect sizes for those who got better were moderate for
MSSID scores and small for the MSQol-54 and LMSQol
scores with one exception (emotional role limitations)
(table 5). Effect sizes for those who got worse were small
for the MSSID, MSQoL-54, and LMSQoL scores. The effect
sizes were in the expected direction for MSSID and LMSQoL
scores, but did not show a consistent pattern for MSQoL-54
scores.
DISCUSSION
This study has provided initial support for the reliability,
validity, and responsiveness of the (MSSID). Response rates
were similar but the rates of missing items were higher
compared with other studies using the MSQol-54, the
LMSQoL, and the MSIS-29.8 9 26 However, response rates
and rates of missing data were similar to other diary
Table 1 Clinical and demographic
characteristics of the sample
Variable No. (%)*
Age
Mean 46
SD 10
Range 22–68
Length of time since diagnosis
Mean 11
SD 8
Range 1–31
Gender
Male 12 (19)
Female 51 (81)
Clinical course
RR/benign 29 (46)
Progressive 34 (54)
Work status
In paid work 16 (27)
Not in paid work 34 (73)
Taking beta interferon
Yes 15 (24)
No 43 (68)
Relapse during the study
Yes 20 (33)
No 41 (67)
*Percentage of those who responded to each question.
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studies,18 22 providing initial evidence for the diary’s feasi-
bility and acceptability. None of the items had ceiling effects
and only three items had floor effects. These three items,
"weakness or heaviness in your legs", "problems with your
bladder and bowel", and "feeling frustrated" were retained
because the developmental work indicated that they are
both common and important problems for people with
MS. Further work will evaluate whether excluding these
items has an impact on the psychometric properties of the
MSSID.
The majority of items in the MSSID focus on the physical
symptoms of MS and their impact on daily activities, which is
similar to the item content of the MSIS-29.9 However, like the
MSIS-29, it also includes important items that address the
emotional impact of the condition. The MSSID consists of
three factors that measure mobility, the cognitive and
emotional aspects of fatigue, and the overall impact of MS.
These factors are internally reliable and their test–retest
reliability was adequate for group comparisons for weekly
mobility, fatigue, and overall impact scores, and individual
comparisons for daily mobility and fatigue scores. The MSSID
was able to discriminate between people with progressive and
relapsing remitting MS, between those who used a walking
aid and those who did not, and between those who had
recently experienced a relapse and those who had not. It
demonstrated expected moderate associations with appro-
priate scales on the MSQoL-54, the LMSQoL, the Barthel
Index, the LHS, and the RNLI. Although there was some
overlap in the constructs measured by the factor scores, they
assess the impact of mobility, fatigue, and MS as a whole on
daily activities.
Compared with the MSQoL-54 and the LMSQoL, the
responsiveness of the median weekly MSSID scores was
similar or better. The MSSID was better able to detect short
term improvements in functioning than worsening, which
may be attributable to the floor effects in the three items. It
was also more responsive to short term improvements in
functioning than the MSQoL-54 and the LMSQoL. This is in
contrast to a previous study that found an asthma diary to
have lower responsiveness compared with an asthma
questionnaire. The better short term responsiveness of the
MSSID may be because it was explicitly designed to detect
short term changes in functioning, whereas the MSQoL-54
and the LMSQoL were not. The MSSID thus provides a
valuable complement to currently existing instruments in its
measurement of short term changes and day to day
fluctuations in functioning.
The sample size used in the study was small compared with
those used to develop the LMSQoL, the MSIS-29, and the
MSQoL-54.8 9 26 However, it was expected to be sufficient to
provide accurate estimates of the psychometric properties of
the MSSID because sample sizes as low as 20 for reliability
estimates and 40 for validity estimates did not alter the
psychometric interpretation of the MSIS-29 compared with a
sample size of 713.38 The sample was recruited from
outpatient clinics, and a third of respondents experienced a
relapse during the study, reflecting previous research that
people with MS attending outpatient clinics are more likely
to experience relapses or have greater disability for their age
than community based populations.39 Therefore, further
testing of the psychometric properties of the MSSID in a
community based sample of people with MS would be
valuable.
This study suggests that the MSSID could be used in
clinical trials of both disease modifying drugs and interven-
tions to manage MS symptoms. The MSSID may be a useful
Table 2 Internal and test–retest reliability analysis of the MSSID
Reliability estimate n Mobility Fatigue Overall impact
Items included in the factor Unsteadiness or loss of balance.
Weakness or heaviness in your
legs. Muscle stiffness or spasms.
Altered or loss of sensation. Pain.
Loss of co-ordination or dexterity.
Problems with bladder/bowel
Feeling frustrated. Feeling sad
or down. Weakness or
heaviness in your arms.
Fatigue or lack of energy.
Difficulties thinking clearly, or
forgetting things
To what extent did MS stop you from doing
what you wanted to do? Compared with
what you usually do, how much were you
able to do today? On the basis of how your
MS has been, how would you describe
today? How would you describe your health
today?
Cronbach’s alpha 59 0.88–0.90 0.78–0.88 0.86
Item2total correlations 59 0.55–0.81 0.50–0.79 0.50–0.81
ICC of week 1 and week 4 median
scores in stable respondents
26 0.93 0.79 0.70
ICC of daily factor scores on first
stable consecutive days in each month
61 0.95–0.98 0.89–0.96 0.75–0.78
Table 3 Discriminant validity analysis of the MSSID
Clinical group n
Mobility Fatigue Overall impact
Median
Mean
rank Median
Mean
rank Median
Mean
rank
Relapsing remitting 29 4.4 40 4.4 36 3.5 38
Progressive 34 3.6 26 4.3 29 3.3 27
M-W 278 (p = 0.003) 382 (p = 0.123) 315 (p = 0.012)
Walked unaided 31 4.36 39 4.6 38 3.5 38
Used walking aid 32 3.5 24 4.1 36 3.25 25
M-W 245 (p = 0.001) 291 (p = 0.007) 277 (p = 0.004)
Relapse in previous 3
months
21 3.6 25 4 23 3.25 24
No relapse in previous
3 months
38 4.2 33 4.6 34 3.5 34
M-W 295 (p = 0.098) 245 (p = 0.02) 264 (p = 0.03)
M-W, Mann-Whitney U test.
Results with statistical significance are in bold.
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tool to monitor the occurrence of relapses and measure their
impact in a psychometrically robust way. The MSSID is likely
to require more resources to collect and manage the data and
further research is required to assess the feasibility of its use
in the context of a randomised controlled trial. However, as
symptom diaries are sometimes used in current trials of MS
therapies15 but are rarely psychometrically evaluated, the
MSSID represents a significant advance in this respect.
The MSSID may also be useful in routine clinical practice
in providing the patient with a prompt to inform clinicians
about new symptoms or a worsening of existing symptoms,
thus reducing the uncertainty around the occurrence of a
relapse.16 It can also provide a graphical display of changes in
the impact of symptoms over time and may be useful to
clinicians in monitoring responses to treatment. Further
work is needed to explore the most appropriate and feasible
method of presenting MSSID data to clinicians and to
examine clinicians’ and patients’ views of the utility of this
data.
CONCLUSIONS
This study provided initial evidence that the MSSID is
reliable, valid and responsive to change. It may provide a
useful complement to currently available instruments to
measure the outcomes of MS within clinical trials or clinical
practice. Further research is needed to explore its feasibility
and utility to clinicians in randomised controlled clinical
trials and within routine clinical practice.
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Lluis Barraquer i Roviralta and the origins of torsion dystonia
I
diopathic torsion dystonia has the synonyms of dysbasia
lordotica progressiva, dystonia lenticularis, dystonia mus-
culorum deformans, and progressive torsion spasm.
Standard references suggest the first description was that of
Marcus Walter Schwalbe from Ziehen’s clinic in 1907.1
Hermann Oppenheim2 and Georg Theodor Ziehen3 in 1911
published simultaneous reports and in the same year the
Polish neurologists Edward Flatau and Wladyslaw Sterling
described the condition. Oppenheim had described four new
cases in Jewish children and deserves credit for the term
dystonia musculorum deformans and for describing its
‘‘dromedary gait’’.
But the grandson of Lluis Barraquer i Roviralta (1855–
1928) has made a case4 for his prior claim. In 1897 ‘‘he
related the characteristics signs, variably distorted posture
and deformity of movements of the trunk, and limbs, with
muscular spasms’’. However, he described them as athetosis
not dystonia.
Lluis Barraquer i Roviralta was born in Barcelona in 1855.
He was the seventh son of two lawyers from Sta. Cristina de
Aro. He studied medicine in Barcelona in the Hospital of the
Sta. Creu where, a year later, a clinic of electrotherapy was
created for him because he was influenced by Guillaume B
Duchenne’s work on electrical techniques. It was in the
Catalan medical newspaper that he presented his paper,
Contribution to the study of the atetosis.5 According to his
grandson Lluis Barraquer, it was ‘‘a remarkable clinical
observation under the influence of W Hammond, described
as ‘‘double atetosis’’’’.6
In 1906 Barraquer i Roviralta published the first observa-
tion of lipodistrofia cefalotora´cica, known as ‘‘disease of
Barraquer-Simons’’; and in 1828 he published in Annals of the
Hospital of the Sta. Creu an experimental study of the
degeneration and regeneration of the peripheral nervous
system. In 1921 he described the tonic foot reflex
(Barraquer’s reflex).7 His personal life was marred by the
death of his two wives and his son. He died of pneumonia in
1928.
Although the idiopathic torsion dystonia (ITD) phenotype
may be determined in part by non-genetic factors or an allelic
modifying gene,8 there are at least seven clinically distinct
types of hereditary dystonia. Except for the X linked form, all
are inherited as autosomal dominant traits with low
penetrance. Idiopathic torsion dystonia is a clinically and
genetically heterogeneous movement disorder. A GAG dele-
tion (The DYT1 gene) is responsible for early-onset ITD in the
Ashkenazi Jews and in certain non-Jewish families. It maps
to chromosome 9q32-34 with an autosomal dominant
transmission9 and an onset between ages 5 and 15 years.
Cases with no family history are thought to result from
reduced penetrance.
J M S Pearce
304 Beverley Road, Anlaby, Hull HU10 7BG, UK;
jmspearce@freenet.co.uk
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